Article

A history of thrombolytic therapy.

Department of Vascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Journal of Endovascular Therapy (impact factor: 2.86). 01/2005; 11 Suppl 2:II128-133. DOI:10.1583/04-1340.1 pp.II128-133
Source: PubMed

ABSTRACT Thrombolytic therapy has been available for the last 5 decades, but the modern era of thrombolysis began in the early 1990s, with the execution of 3 multicenter trials designed to compare this potentially less invasive therapy to the then standard of care for acute limb ischemia, open surgical revascularization. Even with the development of several bio-engineered lytic agents, the major risk of thrombolytic therapy continues to be bleeding complications. Nevertheless, data exist to suggest that thrombolysis should be considered as an adjunct to open surgery, percutaneous interventions, or, occasionally, as sole therapy for acute vascular occlusion. This review summarizes the developmental milestones in the history of thrombolysis and reviews data supporting its use in acute arterial occlusions.

0 0
 · 
0 Bookmarks
 · 
30 Views
  • Source
    Article: CONVENTIONAL THROMBOLYTICS NEED TO REFINE AT MOLECULAR LEVEL FOR SAFE AND EFFICIENT MANAGEMENT OF CEREBROVASCULAR DISORDERS- AN OVERVIEW
    MAHENDRA K. VERMA, YOGENDRA K. VERMA
    [show abstract] [hide abstract]
    ABSTRACT: The cardio and cerebral disorder are the leading cause of vascular traumas which led to many lives threatening consequences and mortality worldwide. In the last few decades numerous artificial molecules have been implemented in clinical application for management and to overcome with devastating vascular traumas. The management of cardiovascular disorders has made remarkable land mark in the health care system with potential thrombolytic agents. Many of artificial fibrinolytic molecules have been used clinically and many more are in refinement phases to tackle the problem. In this study we have composed evolution of thrombolytics from various sources and refinement with technologies. Though these molecules are quite effective for cardiovascular management but often get fail in case of cerebral traumas. The aim of current study is to have an overview on external fibrinolytic molecules their development and clinical applications. Further we have emphasized on the cerebral vascular disorder and their management with currently available thrombolytic molecules. Further we have summarized toxicity offered by conventional thrombolytic in management of cerebral vascular disorder. Finally we have concluded naval approaches which could be further for management of cerebral vascular traumas
    International Journal of Pharmacy and Pharmaceutical Sciences 03/2013; 5(1):448-454.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

3 multicenter trials
 
acute arterial occlusions
 
acute limb ischemia
 
acute vascular occlusion
 
bio-engineered lytic agents
 
complications
 
developmental milestones
 
last 5 decades
 
major risk
 
modern era
 
open surgical revascularization
 
percutaneous interventions
 
review summarizes
 
reviews data
 
Thrombolytic therapy
 

Kenneth Ouriel